Cargando…

Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816975/ http://dx.doi.org/10.2147/BTT.S54093

Ejemplares similares

Treatment and management of myelofibrosis in the era of JAK inhibitors
por: Keohane, Clodagh, et al.
Publicado: (2013)

Corrigendum to “The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors” [Pharmacol. Res. 147 (2019) 104392]
por: Bechman, Katie, et al.
Publicado: (2020)

CORRIGENDUM to The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma
Publicado: (2019)

Corrigendum to “High on Cannabis and Calcineurin Inhibitors: A Word of Warning in an Era of Legalized Marijuana”
por: Hauser, Naomi, et al.
Publicado: (2018)

Nephrotic syndrome in primary myelofibrosis with renal extramedullary hematopoiesis and glomerulopathy in the JAK inhibitor era
por: Del Sordo, Rachele, et al.
Publicado: (2017)

Corrigendum to Artificial Intelligence in the Era of Precision Oncological Imaging
Publicado: (2023)

Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors
por: Knight, Emily A., et al.
Publicado: (2015)

The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma
por: Derenzini, E, et al.
Publicado: (2014)

The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review
por: Tiribelli, Mario, et al.
Publicado: (2019)

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
por: Pardanani, A, et al.
Publicado: (2013)

Corrigendum to “JAK2/STAT3 Pathway Was Associated with the Protective Effects of IL-22 on Aortic Dissection with Acute Lung Injury”
por: Ren, Wei, et al.
Publicado: (2019)

Will JAK1/2 inhibitors change the standard of care for myelofibrosis?
por: Jung, Chul Won
Publicado: (2012)

Cutaneous cryptococcosis in a patient with myelofibrosis receiving JAK‐inhibitor
por: Chen, Jui‐Che, et al.
Publicado: (2021)

Russian guidelines for the management of COPD: algorithm of pharmacologic treatment [Corrigendum]
Publicado: (2019)

Corrigendum to “Management of endometriosis-related infertility: Considerations and treatment options”
por: Lee, Dayong, et al.
Publicado: (2020)

Corrigendum: Molecular characterization of serogroup 19 Streptococcus pneumoniae in the Czech Republic in the post-vaccine era
por: Žemličková, Helena, et al.
Publicado: (2018)

Corrigendum to: IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era
por: Minh, Bui Quang, et al.
Publicado: (2020)

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives
por: Bose, Prithviraj, et al.
Publicado: (2020)

The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes
por: Mascarenhas, John O., et al.
Publicado: (2022)

Corrigendum to “New Issues in the Management of Osteoporosis”
por: Sirola, Joonas, et al.
Publicado: (2017)

Corrigendum to: Personalized Management of Pheochromocytoma and Paraganglioma
Publicado: (2021)

Corrigendum to “Salvianolic Acid B Protects Intervertebral Discs from Oxidative Stress-Induced Degeneration via Activation of the JAK2/STAT3 Signaling Pathway”
por: Dai, Shouqian, et al.
Publicado: (2022)

Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis
por: Tvorogov, Denis, et al.
Publicado: (2018)

Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis
por: Kuykendall, Andrew T., et al.
Publicado: (2020)

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine. [Corrigendum]
por: Nanda, K, et al.
Publicado: (2013)

Parkinson’s disease managing reversible neurodegeneration [Corrigendum]
Publicado: (2016)

Corrigendum: Lymphangiographic Interventions to Manage Postoperative Chylothorax
por: Jeong, Hyuncheol, et al.
Publicado: (2020)

Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations
por: Barraco, D, et al.
Publicado: (2016)

Corrigendum to “HDAC and HMT Inhibitors in Combination with Conventional Therapy: A Novel Treatment Option for Acute Promyelocytic Leukemia”
por: Vitkevičienė, Aida, et al.
Publicado: (2020)

Corrigendum to “Apoptosis Induced by Tanshinone IIA and Cryptotanshinone Is Mediated by Distinct JAK/STAT3/5 and SHP1/2 Signaling in Chronic Myeloid Leukemia K562 Cells”
por: Jung, Ji Hoon, et al.
Publicado: (2018)

Repeated Intravenous Administration of Silica Nanoparticles Induces Pulmonary Inflammation and Collagen Accumulation via JAK2/STAT3 and TGF-β/Smad3 Pathways in vivo [Corrigendum]
Publicado: (2023)

The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation
por: Ikeda, Kazuhiko, et al.
Publicado: (2017)

Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia [Corrigendum]
Publicado: (2015)

Corrigendum to “Recommendations for Diagnosis and Management of Osteoporosis in COPD Men”
por: Mazokopakis, Elias E., et al.
Publicado: (2017)

Profile of eliglustat tartrate in the management of Gaucher disease [Corrigendum]
Publicado: (2016)

Corrigendum to: Management of Tricuspid Regurgitation: The Role of Transcatheter Therapies
por: Taramasso, Maurizio, et al.
Publicado: (2020)

Corrigendum: Diabetes: how to manage chronic kidney disease
Publicado: (2022)

Corrigendum to: A Comprehensive Algorithm for Management of Neuropathic Pain
Publicado: (2022)

Efficacy of Emerging Technologies to Manage Childhood Obesity [Corrigendum]
Publicado: (2023)

Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor
por: Tremblay, Douglas, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k0helllcbqad2gpsg5mjm0s18n